Prostate Cancer Trial, Recruiting NCT07142967 Sponsor: NYU Langone Health Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07142967
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a male aged 18 or older
  • A biopsy has confirmed prostate cancer that has come back inside the prostate after you previously received external beam radiation therapy (a type of radiotherapy)
  • Your biopsy results show active, living cancer cells that can be graded by a pathologist (using something called a Gleason score)
  • Your testosterone level is at or above 50 ng/dL, tested within the last 2 months before joining (previous hormone therapy is okay as long as your testosterone is currently above this level)
  • At least 4 weeks have passed since any major surgery
  • You are generally in good health and able to carry out most normal daily activities (confirm with trial site)
  • Your prostate is smaller than 90 cc in size, as measured by an MRI scan
  • Your urinary symptom score (a standard questionnaire about bladder and urination) is 20 or below
  • You are able and willing to attend follow-up appointments for at least 2 years, and be contactable for up to 5 years
  • An MRI scan shows a visible area of concern within your prostate
  • You are willing and able to have an MRI scan and complete the standard MRI safety screening form

Who may not be able to join:

  • You have previously had brachytherapy (internal radiation seeds or implants) for prostate cancer
  • You are currently receiving hormone therapy (such as androgen deprivation therapy) or anti-androgen medications
  • Scans (CT, MRI, or PET) show that cancer has spread outside the prostate
  • Scans suggest that one or more lymph nodes may be affected by cancer
  • You have had another cancer in the past 2 years, unless it was certain types of treated skin cancer, a superficial bladder cancer, or another cancer that has been fully in remission for at least 3 years
  • You have Crohn's disease or ulcerative colitis
  • You are unable to have an MRI scan for reasons such as having a pacemaker, a defibrillator, certain metal implants or electronic devices in your body, severe claustrophobia, or being unable to lie flat for the length of the scan
  • You have a metal implant or device in your pelvis area that could interfere with MRI image quality
  • Your body size does not meet the specific measurements required for a particular type of MRI imaging used in this trial (confirm with trial site)
  • You have a known allergy or medical reason preventing you from receiving gadolinium contrast dye or a specific type of imaging agent used in PET scans
  • Your general health and ability to perform daily activities falls below the required level
  • You experienced severe side effects (grade 3 or higher) from your original course of radiotherapy
  • Less than 2 years have passed since your prostate cancer was last treated or considered under control
  • You had a procedure called TURP (a surgical treatment for urinary problems involving the prostate) within the last year
  • You have previously had HIFU (high-intensity focused ultrasound) or cryotherapy treatment for prostate cancer
  • You have a history of urethral stricture (narrowing of the tube you urinate through)
  • You are not able to give informed consent to take part in the trial
  • You are not able to complete quality of life questionnaires

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Zelefsky, MD, NYU Langone Health

Phone: 646-239-9083

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 August 2025
Est. completion
1 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Late toxicity (after 90 days) radiation-associated genitourinary (GU) and gastrointestinal (GI) events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov